PMID- 22303912
OWN - NLM
STAT- MEDLINE
DCOM- 20131115
LR  - 20130208
IS  - 1875-6212 (Electronic)
IS  - 1570-1611 (Linking)
VI  - 11
IP  - 1
DP  - 2013 Jan
TI  - Soluble epoxide hydrolase inhibitors and cardiovascular diseases.
PG  - 105-11
AB  - BACKGROUND: Epoxyeicosatrienoic acids (EETs) have been shown to play a role in 
      cardiovascular protection by reducing ischemia reperfusion injury, producing 
      anti-inflammatory effects, and promoting angiogenesis. EETs are regulated through 
      conversion to less active corresponding diols by soluble epoxide hydrolase (sEH). 
      Inhibition of sEH enhances the beneficial properties of EETs and has been 
      investigated as a possible treatment for cardiovascular diseases. CONTENT: sEH 
      inhibitors (sEHIs) have anti-inflammatory effects by stabilizing 
      anti-inflammatory EETs. Additionally, sEHIs strongly inhibit and reverse cardiac 
      hypertrophy. sEHIs have been shown to protect myocardial cells from 
      ischemiareperfusion injury, treat atherosclerosis and prevent the development of 
      hypertension. sEHIs promote blood vessels to release bradykinin via an 
      EET-mediated STAT3 signaling pathway to elicit tolerance to ischemia. SUMMARY: 
      Inhibition of sEH has been shown to improve several aspects of cardiovascular 
      diseases, including inflammation, hypertension, cardiac hypertrophy and 
      atherosclerosis. For this reason, sEHIs are promising new pharmaceutical for the 
      treatment of cardiovascular diseases.
FAU - Wang, Zhen-He
AU  - Wang ZH
AD  - Department of Cardiology, Second Xiangya Hospital, Central South University, 
      Changsha 410011, P.R. China.
FAU - Davis, Benjamin B
AU  - Davis BB
FAU - Jiang, De-Qian
AU  - Jiang DQ
FAU - Zhao, Ting-Ting
AU  - Zhao TT
FAU - Xu, Dan-Yan
AU  - Xu DY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Vasc Pharmacol
JT  - Current vascular pharmacology
JID - 101157208
RN  - 0 (Enzyme Inhibitors)
RN  - EC 3.3.2.- (Epoxide Hydrolases)
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/*drug therapy/*enzymology/metabolism
MH  - Enzyme Inhibitors/*pharmacology
MH  - Epoxide Hydrolases/*antagonists & inhibitors/*metabolism
MH  - Humans
MH  - Myocytes, Cardiac/*drug effects/enzymology/metabolism
EDAT- 2012/02/07 06:00
MHDA- 2013/11/16 06:00
CRDT- 2012/02/07 06:00
PHST- 2011/09/26 00:00 [received]
PHST- 2011/12/12 00:00 [revised]
PHST- 2011/12/20 00:00 [accepted]
PHST- 2012/02/07 06:00 [entrez]
PHST- 2012/02/07 06:00 [pubmed]
PHST- 2013/11/16 06:00 [medline]
AID - CVP-EPUB-20120206-003 [pii]
PST - ppublish
SO  - Curr Vasc Pharmacol. 2013 Jan;11(1):105-11.